These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37969092)

  • 1. Predictors for non-attainment of meropenem target concentrations when treating infections in critically ill patients
.
    Zheng SJ; Xu Y; Chen ND; Hao JW; Zhu Y; Jie Q
    Int J Clin Pharmacol Ther; 2024 Jan; 62(1):1-7. PubMed ID: 37969092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
    Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of risk factors to predict target concentration non-attainment in critically ill patients prior to empiric β-lactam therapy.
    Imani S; Buscher H; Day R; Gentili S; Jones GRD; Marriott D; Norris R; Sandaradura I
    Eur J Clin Microbiol Infect Dis; 2018 Nov; 37(11):2171-2175. PubMed ID: 30120647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
    Carlier M; Carrette S; Roberts JA; Stove V; Verstraete A; Hoste E; Depuydt P; Decruyenaere J; Lipman J; Wallis SC; De Waele JJ
    Crit Care; 2013 May; 17(3):R84. PubMed ID: 23642005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented or Suspected Gram-Negative Infections.
    Gatti M; Rinaldi M; Laici C; Siniscalchi A; Viale P; Pea F
    Antibiotics (Basel); 2023 Nov; 12(11):. PubMed ID: 37998801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT).
    Abdulla A; Dijkstra A; Hunfeld NGM; Endeman H; Bahmany S; Ewoldt TMJ; Muller AE; van Gelder T; Gommers D; Koch BCP
    Crit Care; 2020 Sep; 24(1):558. PubMed ID: 32933574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.
    Kaska M; Havel E; Selke-Krulichova I; Safranek P; Bezouska J; Martinkova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative LC-MS/MS and HPLC-UV Analyses of Meropenem and Piperacillin in Critically Ill Patients.
    Paal M; Heilmann M; Koch S; Bertsch T; Steinmann J; Höhl R; Liebchen U; Schuster C; Kleine FM; Vogeser M
    Clin Lab; 2019 Sep; 65(9):. PubMed ID: 31532096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic drug monitoring of meropenem and piperacillin-tazobactam in the Singapore critically ill population - A prospective, multi-center, observational study (BLAST 1).
    Chua NG; Loo L; Hee DKH; Lim TP; Ng TM; Hoo GSR; Soong JL; Ong JCL; Tang SSL; Zhou YP; Lee W; Lee LS; Cove M; Ling LM; Kwa AL
    J Crit Care; 2022 Apr; 68():107-113. PubMed ID: 34999376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with meropenem pharmacokinetic/pharmacodynamic target attainment in septic critically ill patients treated with extended intermittent infusion or continuous infusion.
    Tournayre S; Mathieu O; Villiet M; Besnard N; Brunot V; Daubin D; Platon L; Corne P; Klouche K; Larcher R
    Int J Antimicrob Agents; 2023 Aug; 62(2):106868. PubMed ID: 37244425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients.
    Schoenenberger-Arnaiz JA; Ahmad-Diaz F; Miralbes-Torner M; Aragones-Eroles A; Cano-Marron M; Palomar-Martinez M
    Eur J Hosp Pharm; 2020 Mar; 27(e1):e30-e35. PubMed ID: 32296502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study.
    Dhaese SAM; Thooft ADJ; Farkas A; Lipman J; Verstraete AG; Stove V; Roberts JA; De Waele JJ
    J Crit Care; 2019 Aug; 52():75-79. PubMed ID: 30986758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
    Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
    Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Therapeutic Target Attainment of Meropenem in Pediatric Post-Liver Transplant Patients: Extended vs Intermittent Infusion.
    Morales Junior R; Juodinis VD; Telles JP; Romano P; Duarte NJC; De Souza DC; Santos SRCJ
    Transplant Proc; 2023 Dec; 55(10):2456-2461. PubMed ID: 37923571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low attainment to PK/PD-targets for β-lactams in a multi-center study on the first 72 h of treatment in ICU patients.
    Smekal AK; Furebring M; Eliasson E; Lipcsey M
    Sci Rep; 2022 Dec; 12(1):21891. PubMed ID: 36535989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients.
    De Waele JJ; Lipman J; Akova M; Bassetti M; Dimopoulos G; Kaukonen M; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Udy AA; Starr T; Wallis SC; Roberts JA
    Intensive Care Med; 2014 Sep; 40(9):1340-51. PubMed ID: 25053248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
    Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A
    Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?
    Esteve-Pitarch E; Gumucio-Sanguino VD; Cobo-Sacristán S; Shaw E; Maisterra-Santos K; Sabater-Riera J; Pérez-Fernandez XL; Rigo-Bonnin R; Tubau-Quintano F; Carratalà J; Colom-Codina H; Padullés-Zamora A
    Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):527-538. PubMed ID: 34131869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study of vancomycin for appropriate dosing in severe infective patients with augmented renal clearance].
    Liu N; Zhang B; Liu Y; Tang J; Dong D; Gu Q
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2018 Jul; 30(7):646-651. PubMed ID: 30045791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.